The historical rank and industry rank for Eris Lifesciences's FCF Margin % or its related term are showing as below:
NSE:ERIS'
s FCF Margin % Range Over the Past 10 Years
Min: -33.08 Med: 19.27 Max: 31.61
Current: 7.74
During the past 13 years, the highest FCF Margin % of Eris Lifesciences was 31.61%. The lowest was -33.08%. And the median was 19.27%.
NSE:ERIS's FCF Margin % is ranked better than 64.72% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:ERIS: 7.74
Eris Lifesciences FCF Margin % Related Terms
Eris Lifesciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (NSE:ERIS) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eris Lifesciences and its competitors. According to the industry distribution chart, Eris Lifesciences ranks #338 out of 958 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Eris Lifesciences' FCF Margin % too high?
Eris Lifesciences' current FCF Margin % is 0.00%. Based on the distribution chart, Eris Lifesciences ranks #338 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #338 out of 958 companies for FCF Margin %. This puts Eris Lifesciences in the upper half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.12, compared to a current price of ₹1,459.00 — trading 11.2% below its estimated fair value. The current FCF Margin % is 0.00%. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,459.00 is trading 11.2% below its estimated GF Value™ of ₹1,642.12.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for NSE:ERIS:
FCF Margin %: 0.00%
GF Value™: ₹1,642.12 vs. price of ₹1,459.00 (11.2% below fair value)
No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for NSE:ERIS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ERIS has been successfully added to your 
